Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 16 September, 2022
Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting
Dosage: EMULSION;INTRAVENOUS
14
United States
3
Japan
1
China
1
Korea, Republic of
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) | |
US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(12 years from now) | |
US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(12 years from now) |
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 09 November, 2017
Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy
Dosage: EMULSION;INTRAVENOUS
14
United States
3
Japan
1
China
1
Korea, Republic of
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 3 months from now) | |
US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 3 months from now) | |
US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(1 year, 3 months from now) | |
US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 3 months from now) | |
US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 3 months from now) |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS
17
United States
4
Japan
4
European Union
1
Canada
1
China
1
Australia
1
Spain
1
Taiwan
1
Korea, Republic of
1
Hong Kong
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(10 years from now) | |
US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(10 years from now) | |
US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(10 years from now) | |
US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(10 years from now) | |
US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(10 years from now) | |
US11413350 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(11 years from now) | |
US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 12, 2024 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
29
United States
12
Japan
6
China
6
European Union
5
Australia
5
Korea, Republic of
3
Canada
2
Croatia
2
Denmark
2
Spain
2
Portugal
2
Poland
2
Slovenia
2
Mexico
2
RS
2
Hungary
2
Taiwan
2
Lithuania
1
Brazil
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic